Close
Help
Need Help?





JOURNAL

Clinical Medicine Insights: Urology

31,359 Journal Article Views | Journal Analytics

New Pharmacotherapies in the Treatment of Advanced Prostate Cancer

Submit a Paper



Publication Date: 04 Dec 2011

Type: Review

Journal: Clinical Medicine Insights: Urology

Citation: Clinical Medicine Insights: Urology 2010:4 21-35

doi: 10.4137/CMU.S5075

Abstract

Recent drug approvals in the field of prostate cancer therapy have brought about a change in the treatment landscape of locally advanced and metastatic castration-resistant prostate cancer. While this improvement offers a welcoming change in the standard treatment practice of prostate cancer, questions remain with regard to the proper sequencing of the right therapy for the appropriate patient. This review highlights the pre-clinical, safety and clinical studies that help bring to the forefront the drugs recently approved for the treatment of advanced prostate cancer and offer some insights to its use.


Downloads

PDF  (574.52 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)




Our Service Promise

  • Prompt Processing (3 Weeks to Editorial Decision)
  • Fair, Independent Peer Review
  • High Visibility & Extensive Indexing
What Your Colleagues Say About Libertas Academica
testimonial_image
The team at Libertas Academica stands above the pack as publishers of academic journals.  My recent article in Clinical Medicine Insights: Oncology was handled very professionally throughout the process.  They have my highest regards.
Dr Jimmy T Efird (East Carolina University, Greenville, NC, USA)
More Testimonials

Quick Links




Follow Us We make it easy to find new research papers.




SUBJECT HUBS
Author Survey Results
author_survey_results
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.
See Our Results